Achieve Life Sciences, Inc. Proceeds from Debt, Net of Issuance Costs
Achieve Life Sciences, Inc. (ACHV) reported Proceeds from Debt, Net of Issuance Costs of $100.00 thousand for the 9-month period ending 2016-09-30, per its 10-Q filed 2017-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2017-11-09
- 2016-09-30: Proceeds from Debt, Net of Issuance Costs 9 month $100.00K.
| Period end | Proceeds from Debt, Net of Issuance Costs 9 month |
|---|---|
| 2016-09-30 | $100.00K 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |